Compare Coupang Inc (CPNG) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs TG Therapeutics Inc — how do they compare? Coupang Inc trades at $16.32 (market cap $29.34B), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: Coupang Inc is far larger — about 3.9× TG Therapeutics Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.
| CPNG | TGTX | |
|---|---|---|
Market Cap | $29.34B | $7.58B |
Sector | Consumer Cyclical | Health |
52-Week High | $33.53 | $59.06 |
52-Week Low | $15.12 | $26.94 |
Enterprise Value | $28.86B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $16.29, down 1.27% on the day, with a neutral technical signal and bearish moving averages. The company reported revenue of $34.53B in 2025 with a net income of $208M, but recent quarterly earnings have missed expectations. Positive cash flow from operations of $1.77B in 2025 supports ongoing investments, while analyst consensus remains strongly bullish with a $23.38 price target.
The outlook is mixed: strong revenue growth and dominant market position in South Korea offer upside, but consecutive earnings misses, negative net income margin, and high valuation ratios pose risks. Expansion into Taiwan and AI investments present growth catalysts, though regulatory fines and competitive pressures require monitoring.
TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.
The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
